CY1106825T1 - Θεραπεια καρκινων με απλιδινη - Google Patents

Θεραπεια καρκινων με απλιδινη

Info

Publication number
CY1106825T1
CY1106825T1 CY20071101110T CY071101110T CY1106825T1 CY 1106825 T1 CY1106825 T1 CY 1106825T1 CY 20071101110 T CY20071101110 T CY 20071101110T CY 071101110 T CY071101110 T CY 071101110T CY 1106825 T1 CY1106825 T1 CY 1106825T1
Authority
CY
Cyprus
Prior art keywords
aplidine
treatment
cancer
tumors
complementing
Prior art date
Application number
CY20071101110T
Other languages
Greek (el)
English (en)
Inventor
Glynn Thomas Faircloth
Chris Twelves
Luis Paz-Ares
Original Assignee
Pharma Mar S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927006.8A external-priority patent/GB9927006D0/en
Priority claimed from GB0005701A external-priority patent/GB0005701D0/en
Priority claimed from GB0007639A external-priority patent/GB0007639D0/en
Priority claimed from GB0015496A external-priority patent/GB0015496D0/en
Priority claimed from GB0025209A external-priority patent/GB0025209D0/en
Application filed by Pharma Mar S.A. filed Critical Pharma Mar S.A.
Publication of CY1106825T1 publication Critical patent/CY1106825T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20071101110T 1999-11-15 2007-08-30 Θεραπεια καρκινων με απλιδινη CY1106825T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9927006.8A GB9927006D0 (en) 1999-11-15 1999-11-15 Aplidine treatment of cancers
GB0005701A GB0005701D0 (en) 2000-03-09 2000-03-09 Antitumor utility of aplidine
GB0007639A GB0007639D0 (en) 2000-03-29 2000-03-29 Antitumour and anti-angiogenic compound
GB0015496A GB0015496D0 (en) 2000-06-23 2000-06-23 Antitumour and anti-angiogenic compound
GB0025209A GB0025209D0 (en) 2000-10-13 2000-10-13 Treatment of cancers
PCT/GB2000/004349 WO2001035974A2 (en) 1999-11-15 2000-11-15 Aplidine treatment of cancers

Publications (1)

Publication Number Publication Date
CY1106825T1 true CY1106825T1 (el) 2012-05-23

Family

ID=27515929

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101110T CY1106825T1 (el) 1999-11-15 2007-08-30 Θεραπεια καρκινων με απλιδινη

Country Status (27)

Country Link
US (1) US20090298752A1 (enExample)
EP (1) EP1229922B1 (enExample)
JP (1) JP2003514025A (enExample)
KR (1) KR100518986B1 (enExample)
CN (1) CN1423564A (enExample)
AT (1) ATE363910T1 (enExample)
AU (1) AU780417B2 (enExample)
BG (1) BG65381B1 (enExample)
BR (1) BR0015811A (enExample)
CA (1) CA2391502A1 (enExample)
CY (1) CY1106825T1 (enExample)
CZ (1) CZ302498B6 (enExample)
DE (1) DE60035120T2 (enExample)
DK (1) DK1229922T3 (enExample)
ES (1) ES2288486T3 (enExample)
HK (1) HK1045648B (enExample)
HU (1) HUP0203906A2 (enExample)
IL (1) IL149488A0 (enExample)
MX (1) MXPA02004862A (enExample)
NO (1) NO330719B1 (enExample)
NZ (1) NZ518847A (enExample)
PL (1) PL200922B1 (enExample)
PT (1) PT1229922E (enExample)
RU (1) RU2261104C2 (enExample)
SI (1) SI1229922T1 (enExample)
SK (1) SK287762B6 (enExample)
WO (1) WO2001035974A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
NZ525196A (en) 2000-10-12 2004-09-24 Pharma Mar S Treatment of cancers by aplidine in conjunction with a myoprotector
KR20050038578A (ko) * 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
DE60229414D1 (de) * 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
KR20060002778A (ko) 2003-03-12 2006-01-09 파르마 마르, 에스.에이. 개선된 항종양 치료
DK1603584T3 (da) 2003-03-12 2009-01-05 Dana Farber Cancer Inst Inc Aplidine til behandling af multipelt myelom
DK2029155T3 (en) * 2006-02-28 2016-08-01 Pharma Mar Sa IMPROVED treatment of multiple myeloma
ATE479432T1 (de) * 2006-11-03 2010-09-15 Nerviano Medical Sciences Srl Verfahren zur verabreichung einer antitumoralen verbindung
RU2360712C1 (ru) * 2007-10-02 2009-07-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" Способ лечения местно-распространенного неоперабельного рака прямой кишки
CA2703024A1 (en) * 2007-10-19 2009-04-23 Giuseppe Longo Sorbello Improved antitumoral treatments
MX2010009697A (es) * 2008-03-07 2010-09-30 Pharm Mar S A Tratamientos anticancerigenos mejorados.
CN103463020B (zh) * 2013-09-23 2015-11-25 李淑兰 Lycojaponicumin A在制备治疗肾癌药物中的应用
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342744A (en) * 1979-07-19 1982-08-03 Lever Brothers Company Hair treatment products
EP0048149B1 (en) * 1980-09-12 1983-11-30 University of Illinois Foundation Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
DE3684868D1 (de) * 1985-09-20 1992-05-21 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5580871A (en) * 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
WO1995017901A1 (en) * 1993-12-29 1995-07-06 Matrix Pharmaceutical, Inc. Methods and compositions for the treatment of a host with a cellular proliferative disease
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
EP0914116B1 (en) * 1996-05-22 2000-10-11 Protarga Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
EP0981352B8 (en) * 1997-05-07 2009-06-17 Pharma Mar, S.A. Use of aplidine for the treatment of cardiovascular diseases
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
RU2323000C2 (ru) * 2000-04-07 2008-04-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Аналоги тамандарина и дидемнина и способы их получения и применения
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
MXPA03002479A (es) * 2000-10-05 2004-05-24 Immunex Corp Polipeptidos de nectina, polinucleotidos, metodos para elaborarlos y uso de los mismos.
NZ525196A (en) * 2000-10-12 2004-09-24 Pharma Mar S Treatment of cancers by aplidine in conjunction with a myoprotector
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US6610399B1 (en) * 2000-11-17 2003-08-26 Structural Technologies, Llc Multi-layer, thermal protection and corrosion protection coating system for metallic tendons, especially for external post-tensioning systems
DE60229414D1 (de) * 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
DK1603584T3 (da) * 2003-03-12 2009-01-05 Dana Farber Cancer Inst Inc Aplidine til behandling af multipelt myelom
KR20060002778A (ko) * 2003-03-12 2006-01-09 파르마 마르, 에스.에이. 개선된 항종양 치료
EP1613338A4 (en) * 2003-03-21 2009-06-24 Madeleine M Joullie TAMANDARIN ANALOGUES, FRAGMENTS THEREOF AND METHODS OF MAKING AND USING THE SAME
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
DK2029155T3 (en) * 2006-02-28 2016-08-01 Pharma Mar Sa IMPROVED treatment of multiple myeloma
CA2703024A1 (en) * 2007-10-19 2009-04-23 Giuseppe Longo Sorbello Improved antitumoral treatments

Also Published As

Publication number Publication date
ATE363910T1 (de) 2007-06-15
AU1402301A (en) 2001-05-30
NZ518847A (en) 2004-02-27
RU2261104C2 (ru) 2005-09-27
DE60035120D1 (de) 2007-07-19
JP2003514025A (ja) 2003-04-15
BG106714A (en) 2003-02-28
EP1229922A2 (en) 2002-08-14
AU780417B2 (en) 2005-03-17
NO20022293D0 (no) 2002-05-14
PL355335A1 (en) 2004-04-19
RU2002115864A (ru) 2004-01-20
ES2288486T3 (es) 2008-01-16
EP1229922B1 (en) 2007-06-06
WO2001035974A3 (en) 2001-11-01
DK1229922T3 (da) 2007-10-08
NO20022293L (no) 2002-07-05
KR20020064313A (ko) 2002-08-07
SI1229922T1 (sl) 2008-04-30
BR0015811A (pt) 2002-08-06
KR100518986B1 (ko) 2005-10-06
PL200922B1 (pl) 2009-02-27
MXPA02004862A (es) 2003-01-28
BG65381B1 (bg) 2008-05-30
HK1045648B (en) 2007-09-21
HK1045648A1 (en) 2002-12-06
WO2001035974A2 (en) 2001-05-25
CN1423564A (zh) 2003-06-11
PT1229922E (pt) 2007-09-12
CZ20021697A3 (cs) 2003-02-12
SK6592002A3 (en) 2003-08-05
CZ302498B6 (cs) 2011-06-15
HUP0203906A2 (en) 2003-03-28
NO330719B1 (no) 2011-06-20
DE60035120T2 (de) 2008-01-31
SK287762B6 (sk) 2011-09-05
US20090298752A1 (en) 2009-12-03
IL149488A0 (en) 2002-11-10
CA2391502A1 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
CY1106825T1 (el) Θεραπεια καρκινων με απλιδινη
ATE399560T1 (de) Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von nicht-hodgkihn- lymphome
ATE274357T1 (de) Texaphyrin-konjugate und ihre anwendiung
CY2013020I1 (el) Η χρηση μιας ενωσης ινγκενανης για την κατασκευη ενος φαρμακου για την θεραπεια του καρκινου
CY1116616T1 (el) Θεραπευτικη αγωγη ογκων του μαστου με παραγωγο ραπαμυκινης σε συνδυασμο με εξεμεστανη
IS6375A (is) Lyfjagjöf til öftrunar á blöðruhálskrabbameini
AR033157A1 (es) Uso de proteina alfa de activacion de los fibroblastos ("fapaalfa")bibh1 en el tratamiento del cancer
PL354540A1 (en) Drugs for the treatment of malignant tumours
DE60003583D1 (de) Arylaminderivate und ihre verwendung als antitelomerasemittel
BR9813540A (pt) Produtos de condensação de n-benzil-3-indenilacetamidas substituìdos com aldeìdos heterocìclicos para neoplasia
CA2305790A1 (en) Styryl sulfone anticancer agents
IL97055A0 (en) Pharmaceutical compositions for sensitizing tumor cells comprising quinazolinedione derivatives
WO2000063219A8 (en) Platinum complexes for the treatment of cancer
BG108932A (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
IT1317926B1 (it) Derivati triciclici dell'indolo ad attivita' antiangiogenica.
TR200102576T2 (tr) Kanser tedavisinde radyoaktif sisplatin
DE69807166D1 (de) Prostata-spezifische Antigen Inhibitore
TH1901008214A (th) เกลือชนิดใหม่ของ N-(2,6-ไดเอทธิลฟีนิล)-8-({4-[4-(ไดเมทธิลอะมิโน)พิเพอริดิน-1-อิล]-2-เมทธอกซีฟีนิล}อะมิโน)-1-เมทธิล-4,5-ไดไฮโดร-1H-ไพราโซโล[4,3-h]ควินาโซลีน-3-คาร์บอกซาไมด์ การจัดเตรียมของพวกมัน, และสูตรผสมซึ่งมีมันอยู่
ATE312610T1 (de) Liposomale formulierungen von phenylalanin- derivaten
IT1309179B1 (it) Perfezionamenti ad una sonda-catetere per il trattamento di tumorimediante ipertermia interstiziale indotta da radiofrequenza.
RU2003130928A (ru) Способ комбинированного лечения местно-распространенных злокачественных опухолей трахеи и/или бронхов
DK199900380U3 (da) System for nål til bestråling af bl.a. cancer knuder, f.eks. brystknuder